体外膈肌起搏器在慢性阻塞性肺疾病中的应用效果分析

Analysis of the Effect of Pacemaker in Vitro on Chronic Obstructive Pulmonary Disease

目的分析体外膈肌起搏器在慢性阻塞性肺疾病中的应用效果。方法选取2016年5月—2018年4月期间新疆自治区胸科医院收治的152例慢性阻塞性肺疾病患者,按计算机表法分为研究组和对照组各76例,对照组使用常规治疗方案,研究组在对照组基础上配合体外膈肌起搏器进行治疗。比较两组患者治疗前后血气指标变化情况和临床症状改善情况,以及患者治疗期间并发症发生率。结果治疗后,研究组Pa O2和Pa CO2分别为(8.96±3.61)k Pa和(5.87±3.04)k Pa,均明显优于对照组的(7.81±3.59)k Pa和(6.55±3.08)k Pa,两者之间差异有统计学意义(t=3.740 5,4.061 6;P=0.000 0,0.000 0<0.05);研究组临床症状改善时间均明显短于对照组,研究组并发症发生率为5.26%(4/76),对照组并发症发生率为17.11%(13/50),研究组并发症发生率明显低于对照组,两者之间,差异有统计学意义(P<0.05)。结论体外膈肌起搏器在慢性阻塞性肺疾病患者的治疗中应用时,可显著改善患者临床症状和患者血气指标,提高治疗效果;同时不会产生新的并发症,有利于改善患者的预后。

Objective To analyze the application effect of diaphragmatic pacemaker in patients with chronic obstructive pulmonary disease. Methods A total of 152 patients with chronic obstructive pulmonary disease admitted to the X-ray Clinic from May 2016 to April 2018 in the Autonomous Region of Xinjiang Autonomous Region were divided into study group and control group according to the computer table method. 76 cases were used in the control group. The study group was treated with a diaphragm muscle pacemaker in vitro on the basis of the control group. The changes in blood gas parameters and the improvement of clinical symptoms before and after treatment were compared between the two groups of patients, as well as the incidence of complications during treatment. Results After treatment, Pa O2 and Pa CO2 in the study group were（8.96±3.61）k Pa and（5.87±3.04）k Pa, respectively, which were significantly better than the control group（7.81±3.59）k Pa and（6.55±3.08）k Pa. There was a large difference between the two groups, the data was statistically significant（t=3.740 5, 4.061 6; P=0.000 0, 0.000 00.05）; the improvement time of the clinical symptoms in the study group was significantly shorter than that of the control group. The complication rate in the study group was 5.26%（4/76）, the control group complication rate was 17.11%（13/50）, th e incidence of complications in the study group was significantly lower than the control group, the data were statistically significant（P〈0.05）. Conclusion In vitro application of diaphragmatic pacemaker in the treatment of patients with chronic obstructive pulmonary disease can significantly improve the clinical symptoms and blood gas index of patients, improve the treatment effect; at the same time, it will not produce new complications, and it is beneficial to improve the prognosis of patients.